Type 2 diabetes medications in the SGLT-2 inhibitor class may reduce the risk of dementia by 35% with long-term use, a study published in the journal Neurology showed. BMJ.
The authors analyzed information on 220,000 people from a Korean database. All were between the ages of 40 and 69 and were diagnosed with type 2 diabetes. They did not have dementia at the start of follow-up. Half received SGLT-2 inhibitors, and the other half received DPP-4 inhibitors. Data from each person in the first group were compared with data from a patient of the same age, sex, and health status in the second group.
Dementia was detected in 1,200 patients during the study. There were fewer cases of the disease in the SGLT-2 inhibitor group than in the DPP-4 inhibitor group: 0.22 per 100 people versus 0.35 per 100 people.
This means a 35% reduction in risk. At the same time, the risk of Alzheimer’s disease was reduced by 39% and the risk of vascular dementia was reduced by 52%.
The scientists stressed that their study was observational and therefore could not prove a cause-and-effect relationship. The results could be confirmed by randomized trials in which patients are randomly assigned to receive one of the drugs or a placebo.
Russians before warned about early signs of dementia.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.